619
Participants
Start Date
October 26, 2018
Primary Completion Date
August 15, 2020
Study Completion Date
August 15, 2020
High-dose influenza vaccine
The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
MF59-adjuvanted influenza vaccine
The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
Standard intramuscular influenza vaccine
The control intervention consists in an intramuscular injection of one dose of VaxigripTetra®, the standard non-adjuvanted intramuscular influenza vaccine (as routinely done).
CHUV, Lausanne
Hopitaux Universitaires de Genève, Geneva
University Hospital Bern, Bern
University Hospital Basel, Basel
Epatocentro Ticino, Lugano
Cantonal Hospital Chur, Chur
UniversitätsSpital Zürich, Zurich
Canton Hospital St-Gallen, Sankt Gallen
Hospitales Universitarios Virgen del Rocio, Seville
Oriol Manuel
OTHER
University Hospital, Basel, Switzerland
OTHER
University of Bern
OTHER
University Hospital, Geneva
OTHER
University of Zurich
OTHER
Cantonal Hospital of St. Gallen
OTHER
Fondazione Epatocentro Ticino
OTHER
Cantonal Hospital Chur
UNKNOWN
Hospitales Universitarios Virgen del Rocío
OTHER